In the high-stakes race to secure North America’s lithium future, Volt Lithium Corp. (TSXV: VLT.v – US-OTC: VLTLF), and Standard Lithium Ltd. (SLI) represent two starkly different paths. Standard Lithium’s latest milestone, announced on March 11, 2025, celebrates the Smackover Lithium joint venture (with Equinor) completing its final Direct Lithium Extraction (DLE) derisking step at […]
March 11th Biotech Update
Another day and another big loss in the market. Not even the large cap healthcare names are holding up. I do think we are likely due for a bounce back rally but I also structurally worry about the market going forward. It was pretty highly valued to start with and now with the political uncertainty […]
March 10th Biotech Update
It is actually a pretty good news day for the sector but it does so while the broader markets are collapsing. To be fair, you would expect to see the sector down a lot lower given the broader markets but it is actually outperforming (on a relative basis) really well. So despite having a red […]
March 3rd Biotech Update
The sector saved itself last week but it is a new week and new uncertainties abound. While I am not sure how much play it received or whether it matters, but in light of the measles outbreak in west Texas, RFK wrote an opinion piece for Fox News in which he called the outbreak a […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
